| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10763146 | Biochemical and Biophysical Research Communications | 2011 | 6 Pages |
Abstract
⺠Mechanisms for preadipocyte hyperplasia by pioglitazone, a PPARγ agonist, are shown. ⺠Pioglitazone promotes cell-cycle of 3T3-L1 preadipocytes and increases their number. ⺠Pioglitazone downregulates a cyclin dependent kinase inhibitor, p16Ink4a. ⺠PPARγ transrepresses p16Ink4a gene in preadipocytes, which pioglitazone enhances.
Keywords
FACSCDKIT2DM5-bromo-2-deoxyuridineCDKPPARDAPI4′,6-diamidino-2-phenylindolePreadipocyteBrdUfluorescence-activated cell sortingType 2 diabetes mellitusObesitycyclin-dependent kinase inhibitorcyclin dependent kinase inhibitorhyperplasiaCell-cyclecyclin dependent kinaseperoxisome proliferator-activated receptorperoxisome proliferator-activated receptor γ
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Arif U. Hasan, Koji Ohmori, Takeshi Hashimoto, Kazuyo Kamitori, Yuko Hirata, Yasuhiro Ishihara, Naoko Okamoto, Takahisa Noma, Hiroaki Kosaka, Masaaki Tokuda, Masakazu Kohno,